Stoke Therapeutics (STOK) EBITDA (2018 - 2026)

Stoke Therapeutics' EBITDA history runs 9 years deep, the most recent figure standing at -$50.7 million for Q1 2026.

• In Q1 2026, EBITDA fell 144.86% year-over-year to -$50.7 million; the TTM figure through Mar 2026 stood at -$169.8 million (down 438.42% YoY), while the FY2025 annual figure was -$6.2 million, up 93.05% from the prior year.
• EBITDA was -$50.7 million for Q1 2026 at Stoke Therapeutics, up from -$57.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $112.9 million in Q1 2025 to a low of -$57.8 million in Q4 2025.
• Historically, EBITDA has averaged -$20.7 million across 5 years, with a median of -$25.7 million in 2024.
• Biggest YoY gain for EBITDA was 528.56% in 2025; the steepest drop was 435.58% in 2025.
• A 5-year view of EBITDA shows it stood at -$25.1 million in 2022, then declined by 6.8% to -$26.8 million in 2023, then soared by 59.76% to -$10.8 million in 2024, then slumped by 435.58% to -$57.8 million in 2025, then gained by 12.41% to -$50.7 million in 2026.
• The last three EBITDA figures came in at -$50.7 million (Q1 2026), -$57.8 million (Q4 2025), and -$38.0 million (Q3 2025), per Business Quant data.